Is Rezolute Inc. (RZLT) One of the Top Long-Term Biotechnology Stocks to Buy

Core Viewpoint - Rezolute Inc. (NASDAQ:RZLT) is identified as a top long-term biotechnology stock, with strong confidence in its lead candidate, ersodetug, which is currently in Phase 3 trials for congenital hyperinsulinism [1][2]. Company Overview - Rezolute Inc. is a biopharmaceutical company focused on developing therapies for rare and metabolic diseases, particularly hyperinsulinism (HI), a rare genetic disorder that can lead to dangerously low blood sugar levels [3]. Drug Development - The lead candidate, ersodetug, employs a novel insulin receptor-blocking mechanism and addresses a significant unmet medical need [2]. - If approved, ersodetug is expected to capture substantial market share due to its favorable competitive position [2]. Market Opportunities - There are additional opportunities for Rezolute in related conditions, such as tumor-induced hypoglycemia, which supports a positive long-term outlook for the company [2].